BridgeBio and National Resilience announced a strategic collaboration to manufacture and advance BBP-812, an investigational adeno-associated virus, or AAV, nine gene therapy for Canavan disease, and BBP-631, an investigational AAV 5 gene therapy for congenital adrenal hyperplasia, or CAH.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BBIO:
- BridgeBio and Resilience Announce Strategic Multi-Year Partnership to Advance BBP-631, BBP-812 and Future Gene Therapy Treatments
- Qatar Investment Authority Leads $250M PIPE Financing in BridgeBio (NASDAQ:BBIO)
- BridgeBio announces $250M PIPE financing
- BridgeBio Pharma Announces $250 Million Private Placement Equity Financing
- BridgeBio Pharma put volume heavy and directionally bearish